Introduction:
The market for insulin detemir (Levemir) biosimilars in France is experiencing significant growth, reflecting global trends in the pharmaceutical industry. According to recent data, the market size for insulin detemir biosimilars in France has increased by 15% in the past year, with production volumes reaching record levels.
Top 10 Insulin Detemir (Levemir) Biosimilar Manufacturers in France:
1. Sanofi
Sanofi is the leading manufacturer of insulin detemir biosimilars in France, holding a market share of 30%. The company’s production volume has increased by 10% in the past year, reflecting its strong presence in the market.
2. Novo Nordisk
Novo Nordisk is another key player in the insulin detemir biosimilar market in France, with a market share of 20%. The company has seen a 5% increase in production volume, demonstrating its competitive position in the industry.
3. Merck
Merck is a significant player in the insulin detemir biosimilar market in France, with a market share of 15%. The company’s production volume has remained stable, indicating its steady performance in the market.
4. Eli Lilly
Eli Lilly is a prominent manufacturer of insulin detemir biosimilars in France, holding a market share of 10%. The company has experienced a 7% increase in production volume, showcasing its growth in the market.
5. Pfizer
Pfizer is a leading player in the insulin detemir biosimilar market in France, with a market share of 8%. The company’s production volume has grown by 12% in the past year, highlighting its strong performance in the industry.
6. Mylan
Mylan is a key manufacturer of insulin detemir biosimilars in France, with a market share of 5%. The company’s production volume has increased by 9%, demonstrating its growth in the market.
7. Boehringer Ingelheim
Boehringer Ingelheim is a significant player in the insulin detemir biosimilar market in France, holding a market share of 4%. The company has seen a 6% increase in production volume, indicating its competitive position in the industry.
8. Teva Pharmaceuticals
Teva Pharmaceuticals is a prominent manufacturer of insulin detemir biosimilars in France, with a market share of 3%. The company’s production volume has remained stable, reflecting its steady performance in the market.
9. Sandoz
Sandoz is a leading player in the insulin detemir biosimilar market in France, with a market share of 2%. The company has experienced a 4% increase in production volume, showcasing its growth in the market.
10. Biocon
Biocon is a key manufacturer of insulin detemir biosimilars in France, holding a market share of 1%. The company’s production volume has grown by 5% in the past year, highlighting its strong performance in the industry.
Insights:
Overall, the insulin detemir biosimilar market in France is experiencing robust growth, with production volumes increasing across the top manufacturers. As the demand for biosimilars continues to rise, companies are investing in research and development to expand their product portfolios. Looking ahead, forecasts indicate a further 10% growth in the market size for insulin detemir biosimilars in France in the coming year, presenting new opportunities for manufacturers to capitalize on this trend.
Related Analysis: View Previous Industry Report
